Novo Nordisk Gets Approval in Mexico for Wegovy Tablets and Opens a New Era for LPG-1s in Latin America
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Staff/RG Novo Nordisk's 25 mg oral semaglutide offers people living with obesity or overweight a daily intake pill that provides an average weight loss of 17%. 17% average weight loss: In the OASIS 4 clinical trial, adults who took oral semaglutide 25 mg lost about 17% of their body weight, and 1 in 3 lost 20% or more after 64 weeks.1 A tablet that you simply take and continue with your day: A daily oral option that integrates practically and si…
CORTESY: Novo Nordisk Novo Nordisk announced that the Federal Commission for the Protection against Health Risks (Cofepris) approved in Mexico Wegovy tablets, an oral presentation of semaglutide of 25 milligrams for weight control, a decision that makes the country the first in Latin America to authorize this daily intake treatment. The approval, identified with the health registry 283M2026 SSA IV, contemplates its use to reduce excess body weig…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
